Is EPRX or LKFT more profitable?

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Eupraxia Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eupraxia Pharmaceuticals N/A -63.97% -43.32% Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A

Does the media prefer EPRX or IMCR?

In the previous week, Eupraxia Pharmaceuticals and Eupraxia Pharmaceuticals both had 5 articles in the media. Eupraxia Pharmaceuticals' average media sentiment score of 1.35 beat Immunocore's score of 0.51 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunocore 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SEPN or EPRX?

In the previous week, Eupraxia Pharmaceuticals had 1 more articles in the media than Septerna. MarketBeat recorded 5 mentions for Eupraxia Pharmaceuticals and 4 mentions for Septerna. Septerna's average media sentiment score of 1.44 beat Eupraxia Pharmaceuticals' score of 1.35 indicating that Septerna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eupraxia Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, EPRX or DMRA?

Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eupraxia Pharmaceuticals N/A N/A -$38.58M -$1.02 N/A Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$3.37 N/A

Is EPRX or DMRA more profitable?

Eupraxia Pharmaceuticals' return on equity of -63.97% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Eupraxia Pharmaceuticals N/A -63.97% -43.32% Damora Therapeutics, Inc. Common Stock N/A -176.39% -77.86%

Does the media favor EPRX or VIR?

In the previous week, Vir Biotechnology had 3 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 8 mentions for Vir Biotechnology and 5 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 1.35 beat Vir Biotechnology's score of 1.13 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vir Biotechnology 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Eupraxia Pharmaceuticals (EPRX) Competitors

$7.45 +1.11 (+17.51%)

Closing price 04:00 PM Eastern

Extended Trading

$7.60 +0.15 (+2.01%)

As of 06:40 PM Eastern

Compare

EPRX vs. LKFT, IMCR, SEPN, DMRA, and VIR

Should you buy Eupraxia Pharmaceuticals stock or one of its competitors? Eupraxia Pharmaceuticals's main competitors and comparable companies include Lakefront Biotherapeutics American Depositary Shares (LKFT), Immunocore (IMCR), Septerna (SEPN), Damora Therapeutics, Inc. Common Stock (DMRA), and Vir Biotechnology (VIR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Eupraxia Pharmaceuticals compare to Lakefront Biotherapeutics American Depositary Shares?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Eupraxia Pharmaceuticals currently has a consensus target price of $18.00, suggesting a potential upside of 141.61%. Lakefront Biotherapeutics American Depositary Shares has a consensus target price of $30.67, suggesting a potential upside of 6.44%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Eupraxia Pharmaceuticals is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, Eupraxia Pharmaceuticals had 4 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 5 mentions for Eupraxia Pharmaceuticals and 1 mentions for Lakefront Biotherapeutics American Depositary Shares. Eupraxia Pharmaceuticals' average media sentiment score of 1.35 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.00 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eupraxia Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lakefront Biotherapeutics American Depositary Shares	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-63.97%	-43.32%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Eupraxia Pharmaceuticals. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.02	N/A
Lakefront Biotherapeutics American Depositary Shares	$990.57M	1.92	$363.05M	-$1.41	N/A

Eupraxia Pharmaceuticals has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

Summary

Eupraxia Pharmaceuticals beats Lakefront Biotherapeutics American Depositary Shares on 9 of the 15 factors compared between the two stocks.

How does Eupraxia Pharmaceuticals compare to Immunocore?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Immunocore (NASDAQ:IMCR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

Eupraxia Pharmaceuticals presently has a consensus price target of $18.00, suggesting a potential upside of 141.61%. Immunocore has a consensus price target of $56.38, suggesting a potential upside of 50.86%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.69

In the previous week, Eupraxia Pharmaceuticals and Eupraxia Pharmaceuticals both had 5 articles in the media. Eupraxia Pharmaceuticals' average media sentiment score of 1.35 beat Immunocore's score of 0.51 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eupraxia Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunocore	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

84.5% of Immunocore shares are owned by institutional investors. 10.1% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Eupraxia Pharmaceuticals has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

Immunocore has higher revenue and earnings than Eupraxia Pharmaceuticals. Immunocore is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.02	N/A
Immunocore	$430.78M	4.47	-$35.51M	-$0.37	N/A

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Immunocore's net margin of -4.20%. Immunocore's return on equity of -4.54% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-63.97%	-43.32%
Immunocore	-4.20%	-4.54%	-1.66%

Summary

Immunocore beats Eupraxia Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Eupraxia Pharmaceuticals compare to Septerna?

Septerna (NASDAQ:SEPN) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

Septerna has a beta of 2.3, indicating that its stock price is 130% more volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

In the previous week, Eupraxia Pharmaceuticals had 1 more articles in the media than Septerna. MarketBeat recorded 5 mentions for Eupraxia Pharmaceuticals and 4 mentions for Septerna. Septerna's average media sentiment score of 1.44 beat Eupraxia Pharmaceuticals' score of 1.35 indicating that Septerna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eupraxia Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Septerna currently has a consensus target price of $52.44, suggesting a potential upside of 39.85%. Eupraxia Pharmaceuticals has a consensus target price of $18.00, suggesting a potential upside of 141.61%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Eupraxia Pharmaceuticals is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Septerna's net margin of -24.51%. Septerna's return on equity of -9.57% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-24.51%	-9.57%	-6.28%
Eupraxia Pharmaceuticals	N/A	-63.97%	-43.32%

Eupraxia Pharmaceuticals has lower revenue, but higher earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$98.88M	17.70	-$48.88M	-$0.54	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.02	N/A

Summary

Septerna and Eupraxia Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Eupraxia Pharmaceuticals compare to Damora Therapeutics, Inc. Common Stock?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

Eupraxia Pharmaceuticals' return on equity of -63.97% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-63.97%	-43.32%
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%

Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.02	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A

14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Eupraxia Pharmaceuticals presently has a consensus price target of $18.00, indicating a potential upside of 141.61%. Damora Therapeutics, Inc. Common Stock has a consensus price target of $44.00, indicating a potential upside of 56.14%. Given Eupraxia Pharmaceuticals' higher possible upside, equities analysts clearly believe Eupraxia Pharmaceuticals is more favorable than Damora Therapeutics, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00

In the previous week, Eupraxia Pharmaceuticals had 3 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 5 mentions for Eupraxia Pharmaceuticals and 2 mentions for Damora Therapeutics, Inc. Common Stock. Eupraxia Pharmaceuticals' average media sentiment score of 1.35 beat Damora Therapeutics, Inc. Common Stock's score of 0.70 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eupraxia Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eupraxia Pharmaceuticals has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

Summary

Eupraxia Pharmaceuticals beats Damora Therapeutics, Inc. Common Stock on 8 of the 14 factors compared between the two stocks.

How does Eupraxia Pharmaceuticals compare to Vir Biotechnology?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Vir Biotechnology (NASDAQ:VIR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Eupraxia Pharmaceuticals has higher earnings, but lower revenue than Vir Biotechnology. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.02	N/A
Vir Biotechnology	$302.59M	6.43	-$437.99M	-$1.86	N/A

In the previous week, Vir Biotechnology had 3 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 8 mentions for Vir Biotechnology and 5 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 1.35 beat Vir Biotechnology's score of 1.13 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eupraxia Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vir Biotechnology	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eupraxia Pharmaceuticals currently has a consensus target price of $18.00, indicating a potential upside of 141.61%. Vir Biotechnology has a consensus target price of $21.57, indicating a potential upside of 87.58%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Vir Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Eupraxia Pharmaceuticals has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market.

65.3% of Vir Biotechnology shares are held by institutional investors. 2.9% of Vir Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -29.99% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-63.97%	-43.32%
Vir Biotechnology	-638.88%	-29.99%	-23.62%

Summary

Vir Biotechnology beats Eupraxia Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Eupraxia Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EPRX vs. The Competition

Export

Metric	Eupraxia Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$484.39M	$4.03B	$7.21B	$12.72B
Dividend Yield	N/A	3.61%	2.54%	11.69%
P/E Ratio	-7.30	12.31	273.21	25.05
Price / Sales	N/A	1,291.43	601.13	77.95
Price / Cash	N/A	106.63	77.20	52.85
Price / Book	4.84	16.21	12.86	6.10
Net Income	-$38.58M	-$22.72M	$3.47B	$348.86M
7 Day Performance	0.27%	-1.18%	-0.22%	-1.69%
1 Month Performance	16.41%	12.75%	8.04%	3.57%
1 Year Performance	37.71%	53.86%	25.08%	15.00%

Eupraxia Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EPRX Eupraxia Pharmaceuticals	2.2895 of 5 stars	$7.45 +17.5%	$18.00 +141.6%	+18.3%	$484.39M	N/A	N/A	29	Positive News High Trading Volume
LKFT Lakefront Biotherapeutics American Depositary Shares	0.9595 of 5 stars	$29.44 +1.0%	$30.67 +4.2%	-9.2%	$1.92B	$1.26B	N/A	1,310
IMCR Immunocore	3.5614 of 5 stars	$36.75 -1.0%	$56.38 +53.4%	+14.4%	$1.91B	$400.02M	N/A	320
SEPN Septerna	3.2654 of 5 stars	$40.47 +0.5%	$52.44 +29.6%	+211.4%	$1.88B	$45.95M	N/A	N/A	Gap Up
DMRA Damora Therapeutics, Inc. Common Stock	2.4222 of 5 stars	$30.60 +0.7%	$44.00 +43.8%	+786.0%	$1.88B	N/A	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EPRX) was last updated on 9/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eupraxia Pharmaceuticals (EPRX) Competitors

EPRX vs. LKFT, IMCR, SEPN, DMRA, and VIR

How does Eupraxia Pharmaceuticals compare to Lakefront Biotherapeutics American Depositary Shares?

Summary

How does Eupraxia Pharmaceuticals compare to Immunocore?

Summary

How does Eupraxia Pharmaceuticals compare to Septerna?

Summary

How does Eupraxia Pharmaceuticals compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does Eupraxia Pharmaceuticals compare to Vir Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX vs. The Competition

Eupraxia Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eupraxia Pharmaceuticals (EPRX) Competitors

EPRX vs. LKFT, IMCR, SEPN, DMRA, and VIR

How does Eupraxia Pharmaceuticals compare to Lakefront Biotherapeutics American Depositary Shares?

Do analysts prefer EPRX or LKFT?

Does the media prefer EPRX or LKFT?

Is EPRX or LKFT more profitable?

Do insiders and institutionals hold more shares of EPRX or LKFT?

Which has stronger earnings and valuation, EPRX or LKFT?

Which has more risk and volatility, EPRX or LKFT?

Summary

How does Eupraxia Pharmaceuticals compare to Immunocore?

Do analysts prefer EPRX or IMCR?

Does the media prefer EPRX or IMCR?

Do institutionals & insiders hold more shares of EPRX or IMCR?

Which has more volatility and risk, EPRX or IMCR?

Which has better valuation and earnings, EPRX or IMCR?

Is EPRX or IMCR more profitable?

Summary

How does Eupraxia Pharmaceuticals compare to Septerna?

Which has more risk & volatility, SEPN or EPRX?

Does the media prefer SEPN or EPRX?

Do analysts prefer SEPN or EPRX?

Is SEPN or EPRX more profitable?

Which has better valuation and earnings, SEPN or EPRX?

Summary

How does Eupraxia Pharmaceuticals compare to Damora Therapeutics, Inc. Common Stock?

Is EPRX or DMRA more profitable?

Which has preferable valuation & earnings, EPRX or DMRA?

Do institutionals and insiders believe in EPRX or DMRA?

Do analysts prefer EPRX or DMRA?

Does the media prefer EPRX or DMRA?

Which has more risk & volatility, EPRX or DMRA?

Summary

How does Eupraxia Pharmaceuticals compare to Vir Biotechnology?

Which has better earnings & valuation, EPRX or VIR?

Does the media favor EPRX or VIR?

Do analysts recommend EPRX or VIR?

Which has more volatility and risk, EPRX or VIR?

Do insiders and institutionals have more ownership in EPRX or VIR?

Is EPRX or VIR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX vs. The Competition

Eupraxia Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools